Home > Publications database > CNS tumor with EP300::BCOR fusion: discussing its prevalence in adult population. |
Journal Article (Review Article) | DKFZ-2023-00353 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2023
Biomed Central
London
This record in other databases:
Please use a persistent id in citations: doi:10.1186/s40478-023-01523-y
Abstract: The Central Nervous System (CNS) tumor with BCOR internal tandem duplication (ITD) has recently been added as a novel embryonal histomolecular tumor type to the 2021 World Health Organization (WHO) Classification of CNS Tumors. In addition, other CNS tumors harboring a BCOR/BCORL1 fusion, which are defined by a distinct DNA-methylation profile, have been recently identified in the literature but clinical, radiological and histopathological data remain scarce. Herein, we present two adult cases of CNS tumors with EP300::BCOR fusion. These two cases presented radiological, histopathological, and immunohistochemical homologies with CNS tumors having BCOR ITD in children. To compare these tumors with different BCOR alterations, we performed a literature review with a meta-analysis. CNS tumors with EP300::BCOR fusion seem to be distinct from their BCOR ITD counterparts in terms of age, location, progression-free survival, tumor growth pattern, and immunopositivity for the BCOR protein. CNS tumors from the EP300::BCOR fusion methylation class in adults may be added to the future WHO classification.
Keyword(s): Child (MeSH) ; Adult (MeSH) ; Humans (MeSH) ; Prevalence (MeSH) ; Central Nervous System Neoplasms: genetics (MeSH) ; Biomarkers, Tumor: analysis (MeSH) ; Proto-Oncogene Proteins: genetics (MeSH) ; Proto-Oncogene Proteins: metabolism (MeSH) ; Repressor Proteins: genetics (MeSH) ; E1A-Associated p300 Protein: genetics (MeSH) ; Adult ; BCOR ; EP300 ; Biomarkers, Tumor ; BCOR protein, human ; Proto-Oncogene Proteins ; Repressor Proteins ; EP300 protein, human ; E1A-Associated p300 Protein
![]() |
The record appears in these collections: |